Keywords: Kyowa Hakko, Astellas, Pasetocin, Sawacillin, H pylori, Japan, Dormicum, Hypnosedative
Kyowa Hakko and Astellas get new indication for Pasetocin and Sawacillin; latter applies for new Dormicum use
Article | 21 February 2013
Japanese drug major Kyowa Hakko Kirin (TYO: 4151) and Astellas Pharma (TYO: 4503) have jointly announced that Helicobacter pylori (H. pylori) gastritis ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
